Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.46−0.06 (-1.70%)
Close on Nov 17, 2026Market cap $224.08MP/E –Yield –
Immuneering operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Immuneering's operating cash flow for the twelve months ending Sep 30, 2026 was -$61.56M. For fiscal 2025 it was -$45.34M. The highest annual figure on record is -$14.62M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.34M | – |
| FY2024 | Dec 31, 2024 | -$55.00M | – |
| FY2023 | Dec 31, 2023 | -$48.97M | – |
| FY2022 | Dec 31, 2022 | -$44.10M | – |
| FY2021 | Dec 31, 2021 | -$30.85M | – |
| FY2020 | Dec 31, 2020 | -$14.62M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$16.79M | – |
| Q2 FY2026 | Jun 30, 2026 | -$16.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.78M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.28M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.24M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.03M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.49M | – |
See a number that looks wrong?